LonS.SchneiderMD

Geriatric Psychiatry

Professor of Psychiatry, Neurology, and Gerontology at the Keck School of Medicine of the University of Southern California Director of the California Alzheimer's Disease Center, the Department of Psychiatry Geriatric Studies Center

Join to view full profile

Dr. Schneider is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Schneider's full profile

Already have an account?

Office
1520 San Pablo St
Ste 1652
Los Angeles, CA 90033
Phone+1 323-442-6000

Fax+1 323-442-6001

Education & Training

University of Southern California School of MedicineMS, Applied Biometry and Epidemiology, 1995
University of Southern California/Los Angeles General Medical Center (USC/LA General)Residency, Psychiatry, 1978 - 1983
Drexel University College of MedicineClass of 1978

Certifications & Licensure

CA State Medical License 1979 - 2027
American Board of Psychiatry and Neurology Psychiatry
American Board of Psychiatry and Neurology Geriatric Psychiatry

Awards, Honors, & Recognition

Super Doctor SuperDoctors.com

Clinical Trials

CATIE-Alzheimer's Disease Trial Start of enrollment: 2001 Mar 01
Completed
Not Applicable
Citalopram for Agitation in Alzheimer's Disease Start of enrollment: 2009 Jul 01
Completed
Phase 3
Phytoserms for Menopause Symptoms and Age-Associated Memory Decline Start of enrollment: 2012 Jul 01
Completed
Not Applicable
Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo Start of enrollment: 2013 Jul 01
Terminated
Phase 3
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss Start of enrollment: 2014 Feb 28
Completed
Phase 3
Allopregnanolone for Mild Cognitive Impairment Due to Alzheimer's Disease or Mild AD Start of enrollment: 2014 Aug 01
Completed
Phase 1
Allopregnanolone Regenerative Therapeutic for Early Alzheimer's Disease: Intramuscular Study Start of enrollment: 2019 Oct 01
Active, not recruiting
Phase 1
Development of Novel Measures for Alzheimer's Disease Prevention Trials Start of enrollment: 2019 Feb 25
ACTIVE_NOT_RECRUITING
NA
Join now to see all

Publications & Presentations

PubMed

B vitamins and the 2024 Lancet Commission on dementia.
Gill Livingston, Sergi G Costafreda, Mika Kivimaki, Naaheed Mukadam, Geir Selbaek
Lancet. 2025-02-22
Reflections on The Lancet's Commission on dementia prevention, intervention, and care - Authors' reply.
Gill Livingston, Sergi G Costafreda, Mika Kivimäki, Naaheed Mukadam, Lon S Schneider
Lancet. 2025-02-22
Retinal ganglion cell vulnerability to pathogenic tau in Alzheimer's disease.
Miyah R Davis, Edward Robinson, Yosef Koronyo, Elena Salobrar-Garcia, Altan Rentsendorj
Acta Neuropathologica Communications. 2025-02-15

Press Mentions

Alzheimer's Data WithdrawnNovember 11th, 2024
If Alzheimer's Drug Ads Had More Data, Here's What Might HappenAugust 30th, 2024
Challenges of Anti-Amyloid Therapies in Alzheimer’s Disease: Neurologists’ PerspectivesJuly 30th, 2024
Join now to see all